🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Squamous cell carcinoma of vulva/vagina, Squamous cell carcinoma of the head and neck, Squamous cell carcinoma of penis, Squamous cell carcinoma of cervix, Squamous cell carcinoma of anus

    phase 2 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, TEDOPI

    Ningbo Cancer Hospital

    Platinum sensitive recurrent ovarian cancer

    phase 2 small molecule active

    1 trial

  3. KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion.

    Ningbo Cancer Hospital

    METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)

    phase 2 small molecule active

    1 trial

  4. KN046

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. Kanglaite

    The First People's Hospital of Lianyungang

    Head and Neck Cancer

    phase 2 small molecule completed

    1 trial

  6. LB1410

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  7. LBL-024 for Injection

    The First People's Hospital of Lianyungang

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  8. LEN+SIN+DEB-TACE+HAIC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma Non-resectable

    phase 2 other active

    1 trial

  9. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. LM-108 antibody and sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  11. LOMUSTINE , Odomzo 200 mg hard capsules, VINCRISTINE, CISPLATIN

    Ningbo Cancer Hospital

    Newly Diagnosed Medulloblastoma

    phase 2 small molecule active

    1 trial

  12. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  13. Lactulose

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Constipation

    phase 2 small molecule completed

    1 trial

  14. Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  15. Lanthanum Polystyrene Sulphonate Powder

    The First People's Hospital of Lianyungang

    Hyperphosphatemia

    phase 2 small molecule active

    1 trial

  16. Lenalidomide

    The First People's Hospital of Lianyungang

    PTCL, NOS

    phase 2 small molecule active

    1 trial

  17. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  18. Lenalidomide and Gemcitabine (Dose level 11)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T-cell Lymphomas (PTCL)

    phase 2 small molecule terminated

    1 trial

  19. Lenalidomide combined with G-CHOP (LO CHOP)

    The First People's Hospital of Lianyungang

    DLBCL - Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  20. Lenvatinib

    The First People's Hospital of Lianyungang

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  21. Lenvima 4 mg Oral Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  22. Letrozole

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Uterine Cervical Neoplasms

    phase 2 small molecule active

    1 trial

  23. Lidocaine Hydrochloride, Injectable

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Postoperative Chronic Pain

    phase 2 small molecule active

    1 trial

  24. Lifei Qingchang Granules

    The First People's Hospital of Lianyungang

    Bronchiectasis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources